Novartis’ Sandoz division has announced a new UK headquarters based in Camberley, Surrey.
The global leader in generics and biosimilars announced that it has opened the new building at Watchmoor Park, forming part of the company’s “Transforming Sandoz” strategy, which aims to enable the business to “strengthen its role as a leading provider of medicines to the NHS.”
The company says that the site will be the centre of its UK operations, which encompasses a range of operational functions. It also announced that it is “are hugely excited” to be opening the “new home”, and that “The move is part of our mission to build a long-term future in the UK and to continue working with the NHS to ensure access to generic medicines and biosimilars” said Timothy de Gavre, Sandoz UK country head.
He continued, “Watchmoor Park is the right home for us and our customers; offering convenience, an ideal location and appropriate facilities for our business requirements. As a company, we are on an exciting journey and we look forward to supporting the progress of Watchmoor Park as a thriving
By Anna Smith
Source: PharmaTimes
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
